What is Biomarck Pharmaceuticals?
Biomarck Pharmaceuticals, Ltd. is a clinical-stage biotechnology firm dedicated to addressing inflammatory and immunological conditions. The company leverages a proprietary platform of patent-protected peptides designed to inhibit MARCKS, a key mediator in inflammatory processes. By targeting MARCKS, Biomarck aims to mitigate the severe effects of inflammation, such as acute respiratory distress syndrome (ARDS) and cytokine storm. The company has completed Phase 2 trials for its lead peptide, BIO-11006, across ARDS, chronic obstructive pulmonary disease (COPD), and non-small cell lung cancer (NSCLC), demonstrating promising safety and efficacy profiles for these potential indications. Preclinical research also indicates that inhibiting MARCKS with Biomarck's peptides can impede NSCLC cell migration and metastasis.
How much funding has Biomarck Pharmaceuticals raised?
Biomarck Pharmaceuticals has raised a total of $13M across 2 funding rounds:
Private Equity
$7M
Private Equity
$6M
Private Equity (2013): $7M, investors not publicly disclosed
Private Equity (2016): $6M, investors not publicly disclosed
What's next for Biomarck Pharmaceuticals?
The substantial enterprise-level funding and recent strategic investment signal a pivotal phase for Biomarck Pharmaceuticals. This capital infusion is expected to accelerate the advancement of its peptide-based therapeutics, potentially moving BIO-11006 through further clinical development and regulatory pathways. The company's focus on ARDS, COPD, and NSCLC positions it within critical therapeutic areas with significant unmet needs. Future growth will likely involve expanding clinical trial programs, forging strategic partnerships, and scaling manufacturing capabilities to prepare for potential commercialization. The company's commitment to inhibiting MARCKS offers a novel approach to managing complex inflammatory diseases.
See full Biomarck Pharmaceuticals company page
